A Phase II Study of Neoadjuvant Pemetrexed Plus Cisplatin for Patients with Resectable Non-Squamous Non-Small Cell Lung Cancer with "Switch Chemotherapy Alternative" in Non-Responders (NEOSCAN)

Full Title
Phase II Trial of Neoadjuvant Platinum-Based Chemotherapy of Patients with Resectable Non-small Cell Lung Cancer with Switch Chemotherapy Alternative in Non-responders (NEOSCAN)

Patients with non-small cell lung cancer often require chemotherapy prior to surgery to improve their chance of a cure. Pemetrexed and cisplatin are the best drugs for the treatment of non-squamous non-small cell lung cancer.

This study will use novel ways to monitor shrinkage of the tumor during chemotherapy. Patients will have PET scans before and after chemotherapy.

For patients whose tumor does not shrink, this study will give them a different chemotherapy: vinorelbine and docetaxel. The goal of his study is to measure the safety and effectiveness of switching to a different chemotherapy regimen in patients whose tumor does not shrink using the first chemotherapy.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have stage I-III non-squamous non-small cell lung cancer that can be removed by a surgeon.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Jamie Chaft at 646-888-4545.

Lung Cancer
Lung Cancer, Non-Small Cell: Lung Adenocarcinoma
Related Diseases